Abivax SA (ABVX) Stock Forecast & Price Target

Abivax is supported by compelling Phase 3 ABTECT maintenance data showing obefazimod delivered clinical remission of 51.3% and 50.8% versus 10.4% for placebo, with similarly strong endoscopic outcomes and statistically significant separation across every endpoint. The durability profile also strengthens the thesis, as the Phase 2 open-label maintenance program showed 68% clinical remission at Week 144 by NRI, no new safety signals over up to seven years of cumulative treatment, and increasingly favorable physician sentiment around a potential best-in-disease monotherapy for later-line inflammatory bowel disease. Financially, the company’s ~€1.2B cash balance and runway into 4Q29 reduce near-term funding risk while it advances a 2026–2027 commercialization and pipeline catalyst set, including NDA submission by YE26, combo selection around YE26, and Crohn’s data mid-2027.

Abivax is viewed cautiously because obefazimod, while showing durable ulcerative colitis efficacy and patient-relevant symptom improvements, still faces an increasingly crowded IBD market where combination therapies appear to be setting a higher efficacy bar. The company lacks a disclosed clinical combination program, leaving it behind peers such as AbbVie and JNJ, and even its oral competition from Gilead’s emvistegrast looks increasingly credible, which limits confidence in obefazimod capturing the first advanced-therapy setting. Although Abivax ended the quarter with €402.4MM in cash and raised €767.1MM of net proceeds in July, the outlook remains negative because value creation still depends on later-stage CD data, standard-review UC approval timing, and assumptions that appear already reflected in the shares.